| Name | Title | Contact Details |
|---|---|---|
Andrew Schafer |
Chief Technology Officer | Profile |
Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
Xenotech is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevus sebaceous.